title: The chemokine CCL5 induces CCR1-mediated hyperalgesia in mice inoculated with NCTC 2472 tumoral cells.
abstract: Although the expression of the chemokine receptor CCR1 has been demonstrated in several structures related to nociception, supporting the nociceptive role of chemokines able to activate it, the involvement of CCR1 in neoplastic pain has not been previously assessed. We have assayed the effects of a CCR1 antagonist, J113863, in two murine models of neoplastic hyperalgesia based on the intratibial injection of either NCTC 2472 fibrosarcoma cells, able to induce osteolytic bone injury, or B16-F10 melanoma cells, associated to mixed osteolytic/osteoblastic bone pathological features. The systemic administration of J113863 inhibited thermal and mechanical hyperalgesia but not mechanical allodynia in mice inoculated with NCTC 2472 cells. Moreover, in these mice, thermal hyperalgesia was counteracted following the peritumoral (10-30μg) but not spinal (3-5μg) administration of J113863. In contrast, hyperalgesia and allodynia measured in mice inoculated with B16-F10 cells remained unaffected after the administration of J113863. The inoculation of tumoral cells did not modify the levels of CCL3 at tumor or spinal cord. In contrast, although the concentration of CCL5 remained unmodified in mice inoculated with B16-F10 cells, increased levels of this chemokine were measured in tumor-bearing limbs, but not the spinal cord, of mice inoculated with NCTC 2472 cells. Increased levels of CCL5 were also found following the incubation of NCTC 2472, but not B16-F10, cells in the corresponding culture medium. The intraplantar injection of CCL5 (0.5ng) to naïve mice evoked thermal hyperalgesia prevented by the coadministration of J113863 or the CCR5 antagonist, d-Ala-peptide T-amide (DAPTA), demonstrating that CCL5 can induce thermal hyperalgesia in mice through the activation of CCR1 or CCR5. However, contrasting with the inhibitory effect evoked by J113863, the systemic administration of DAPTA did not prevent tumoral hyperalgesia. Finally, the peritumoral administration of an anti-CCL5 antibody completely inhibited thermal hyperalgesia evoked by the inoculation of NCTC 2472 cells.
authors: Laboratorio de Farmacología, Facultad de Medicina, Instituto Universitario de Oncología del Principado de Asturias (IUOPA), Universidad de Oviedo, c/ Julián Clavería 6, 33006 Oviedo, Asturias, Spain. Electronic address: pevidamarta@uniovi.es.
authors: M
authors: M
authors: Pevida
authors: Laboratorio de Farmacología, Facultad de Medicina, Instituto Universitario de Oncología del Principado de Asturias (IUOPA), Universidad de Oviedo, c/ Julián Clavería 6, 33006 Oviedo, Asturias, Spain. Electronic address: lastraana@uniovi.es.
authors: A
authors: A
authors: Lastra
authors: Centro Comunitario de Sangre y Tejidos del Principado de Asturias, CIBER de Enfermedades Raras (CIBERER), U714, Oviedo, Asturias, Spain. Electronic address: investigacion.ccst@telefonica.net.
authors: Á
authors: Á
authors: Meana
authors: Laboratorio de Farmacología, Facultad de Medicina, Instituto Universitario de Oncología del Principado de Asturias (IUOPA), Universidad de Oviedo, c/ Julián Clavería 6, 33006 Oviedo, Asturias, Spain. Electronic address: hidalgo@uniovi.es.
authors: A
authors: A
authors: Hidalgo
authors: Laboratorio de Farmacología, Facultad de Medicina, Instituto Universitario de Oncología del Principado de Asturias (IUOPA), Universidad de Oviedo, c/ Julián Clavería 6, 33006 Oviedo, Asturias, Spain. Electronic address: arbaiza@uniovi.es.
authors: A
authors: A
authors: Baamonde
authors: Laboratorio de Farmacología, Facultad de Medicina, Instituto Universitario de Oncología del Principado de Asturias (IUOPA), Universidad de Oviedo, c/ Julián Clavería 6, 33006 Oviedo, Asturias, Spain. Electronic address: luismen@uniovi.es.
authors: Luis
authors: L
authors: Menéndez
mesh_terms: D000704:Analysis of Variance; D000818:Animals; D001859:Bone Neoplasms / Q000150:complications*; D045744:Cell Line, Tumor; D018946:Chemokine CCL5 / Q000037:antagonists & inhibitors / Q000378:metabolism*; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004797:Enzyme-Linked Immunosorbent Assay; D007839:Functional Laterality; D015972:Gene Expression Regulation, Neoplastic / Q000502:physiology*; D006930:Hyperalgesia / Q000097:blood / Q000209:etiology* / Q000378:metabolism; D008297:Male; D051379:Mice; D008809:Mice, Inbred C3H; D008810:Mice, Inbred C57BL; D009368:Neoplasm Transplantation / Q000009:adverse effects; D010147:Pain Measurement / Q000187:drug effects; D017288:Pain Threshold / Q000187:drug effects / Q000502:physiology; D015717:Peptide T / Q000627:therapeutic use; D054389:Receptors, CCR1 / Q000037:antagonists & inhibitors / Q000378:metabolism*; D014966:Xanthenes / Q000627:therapeutic use
chemical_list: C515301:Ccr1 protein, mouse; D018946:Chemokine CCL5; D054389:Receptors, CCR1; D014966:Xanthenes; D015717:Peptide T; C055175:peptide T amide; C413447:UCB 35625
keywords: ANOVA; C-C chemokine receptor type 1; C-C chemokine receptor type 5; CCL2; CCL5; CCR1; CCR5; DAPTA; DMEM; DRG; Dulbecco’s modified Eagle’s medium; EDTA; ELISA; FCS; J113863; MIP-1α; PBS; RANTES; TRPV1; analysis of variance; bone cancer-induced pain; chemokine (C-C motif) ligand 2; chemokine (C-C motif) ligand 5; d-Ala-peptide T-amide; dorsal root ganglia; enzyme-linked immunosorbent assay; ethylenediaminetetraacetic acid; fetal calf serum; hyperalgesia; macrophage inhibitory protein-1α; mouse; phosphate-buffered saline; regulated on activation normal T cell expressed and secreted; transient receptor potential vanilloid 1